Literature DB >> 27514586

Lymphangioleiomyomatosis.

Simon R Johnson1, Angelo M Taveira-DaSilva2, Joel Moss3.   

Abstract

Lymphangioleiomyomatosis is a rare multisystem disease predominantly affecting women that can occur sporadically or in association with tuberous sclerosis. Lung cysts progressively replace the lung parenchyma, which leads to dyspnea, recurrent pneumothorax, and in some cases respiratory failure. Patients may also have lymphatic disease in the thorax, abdomen, and pelvis, and renal angiomyolipomas. Treatment includes supportive care, bronchodilators, and for those with progressive disease, mammalian target of rapamycin (mTOR) inhibitors.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Angiomyolipoma; Cystic lung disease; Lymphatic disease; Pneumothorax; mTOR inhibitor

Mesh:

Substances:

Year:  2016        PMID: 27514586     DOI: 10.1016/j.ccm.2016.04.002

Source DB:  PubMed          Journal:  Clin Chest Med        ISSN: 0272-5231            Impact factor:   2.878


  34 in total

Review 1.  Pulmonary Lymphangioleiomyomatosis: A Case Report and Literature Review.

Authors:  Sakda Sathirareuangchai; David Shimizu; Koah Robin Vierkoetter
Journal:  Hawaii J Health Soc Welf       Date:  2020-07-01

Review 2.  Generic Substitution of Orphan Drugs for the Treatment of Rare Diseases: Exploring the Potential Challenges.

Authors:  Antonello Di Paolo; Elena Arrigoni
Journal:  Drugs       Date:  2018-03       Impact factor: 9.546

3.  Long-Term Effect of Sirolimus on Serum Vascular Endothelial Growth Factor D Levels in Patients With Lymphangioleiomyomatosis.

Authors:  Angelo M Taveira-DaSilva; Amanda M Jones; Patricia Julien-Williams; Mario Stylianou; Joel Moss
Journal:  Chest       Date:  2017-05-19       Impact factor: 9.410

4.  Opportunities in Interventional and Diagnostic Imaging by Using High-Performance Low-Field-Strength MRI.

Authors:  Adrienne E Campbell-Washburn; Rajiv Ramasawmy; Matthew C Restivo; Ipshita Bhattacharya; Burcu Basar; Daniel A Herzka; Michael S Hansen; Toby Rogers; W Patricia Bandettini; Delaney R McGuirt; Christine Mancini; David Grodzki; Rainer Schneider; Waqas Majeed; Himanshu Bhat; Hui Xue; Joel Moss; Ashkan A Malayeri; Elizabeth C Jones; Alan P Koretsky; Peter Kellman; Marcus Y Chen; Robert J Lederman; Robert S Balaban
Journal:  Radiology       Date:  2019-10-01       Impact factor: 11.105

5.  Circulating Lymphangioleiomyomatosis Tumor Cells With Loss of Heterozygosity in the TSC2 Gene Show Increased Aldehyde Dehydrogenase Activity.

Authors:  Gustavo Pacheco-Rodríguez; Wendy K Steagall; Leigh Samsel; Pradeep K Dagur; J Philip McCoy; Ilker Tunc; Mehdi Pirooznia; Ji-An Wang; Thomas N Darling; Joel Moss
Journal:  Chest       Date:  2019-04-26       Impact factor: 9.410

6.  Clinical CT underestimation of the percentage volume occupied by cysts in patients with lymphangioleiomyomatosis.

Authors:  Thomas C Larsen; Amir M Hasani; Shirley F Rollison; Tania R Machado; Amanda M Jones; Patricia Julien-Williams; Marcus Y Chen; Joel Moss; Han Wen
Journal:  Clin Imaging       Date:  2019-11-27       Impact factor: 1.605

7.  Genomic rearrangements in sporadic lymphangioleiomyomatosis: an evolving genetic story.

Authors:  Stephen J Murphy; Simone B Terra; Faye R Harris; Aqsa Nasir; Jesse S Voss; James B Smadbeck; Sarah H Johnson; Vishnu Serla; Jay H Ryu; Eunhee S Yi; Benjamin R Kipp; George Vasmatzis; Eva M Carmona
Journal:  Mod Pathol       Date:  2017-06-23       Impact factor: 7.842

8.  Adoptive T-Cell Transfer to Treat Lymphangioleiomyomatosis.

Authors:  Fei Han; Emilia R Dellacecca; Levi W Barse; Cormac Cosgrove; Steven W Henning; Christian M Ankney; Dinesh Jaishankar; Alexander Yemelyanov; Vera P Krymskaya; Daniel F Dilling; I Caroline Le Poole
Journal:  Am J Respir Cell Mol Biol       Date:  2020-06       Impact factor: 6.914

9.  Risk factors for right ventricular dysfunction in patients with lymphangioleiomyomatosis.

Authors:  Wei Hua; Wenbo Yang; Jianing Gu; Jialiang Wu; Wei Wang; Yanpu Liu; Hong Zhu; Min Zhou; Jieming Qu; Yuehua Fang
Journal:  Int J Cardiovasc Imaging       Date:  2020-09-14       Impact factor: 2.357

10.  Rates of change in FEV1 and DLCO as potential indicators for mTOR inhibitor therapy in premenopausal lymphangioleiomyomatosis patients.

Authors:  Angelo M Taveira-DaSilva; Patricia Julien-Williams; Amanda M Jones; Mario Stylianou; Joel Moss
Journal:  Eur Respir J       Date:  2018-04-19       Impact factor: 16.671

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.